Nonoptimal high-density lipoprotein cholesterol levelsare highly prevalent in patients presenting with acutecoronary syndromes and well-controlled low-densitylipoprotein cholesterol levels

Journal of Clinical Lipidology

Volumn 4, Issue 4, 2010, Pages 265-271

  Felix Getzik, Erika M ^a,b   Kuvin, Jeffrey T ^a   Karas, Richard H ^a  

^a Preventive Cardiology Center   (United States)

^b MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Acute coronary syndromes (ACS); Coronary artery disease(CAD); High density lipoprotein cholesterol (HDL C); Myocardial infarction (MI); Unstable angina

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT;

ACUTE CORONARY SYNDROME; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; HUMAN; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; AGED; BLOOD; COHORT ANALYSIS; CORONARY ARTERY DISEASE; FEMALE; MALE; MIDDLE AGED; RISK FACTOR;

ANGINA;

ACUTE CORONARY SYNDROME; AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COHORT STUDIES; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 79551516598     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2010.04.001     Document Type: Article

References (22)

1. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
2. Sacks Fm, Pfeffer MA, Moy LA, et al. The effects on pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
3. Miettinen TA, Gylling H, Strangberg T, Sarna S. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet. 1995;345:1274-1275.
4. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: A randomised placebo-controlled trial. Lancet. 2002;360: 7-22.
5. Simes RJ, Marschner JC, Hunt D, et al. Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in ischemic disease (LIPID) trial. Circulation. 2002;105: 1162-1169.
6. Schwartz GC, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes-The MIRACL Study: A randomized controlled trial. JAMA. 2001;285: 1711-1718.
7. Antman EM, Anbe DT, Kushner FG, et al. ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. J Am Coll Cardiol. 2004;44:671-719.
8. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/- Non-ST-Elevation Myocardial Infarction. J Am Coll Cardiol. 2007; 50:1-157.
9. Canon CP, Braunwald E, McCabe CH, et al. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes (PROVE-IT). N Engl J Med. 2004;350:1495-1504.
10. Brown BG. Direct Comparison of the A to Z and PROVE IT Trials: A Second Chance to Gain a First Impression. Circulation. 2006;113: 1382-1384.
11. Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: Assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol. 2000;86:19L-22L.
12. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: Four prospective American studies. Circulation. 1989;79:8-15.
13. Olsson AG, Schwarts GG, Szarek M, et al. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence shortterm prognosis after acute coronary syndrome: Results from the MIRACL trial. Eur Heart J. 2005;26:890-896.
14. Cannon CP, Battler A, Brindis RG, et al. American College of Cardiology Key Data Elements and Definitions for Measuring Clinical Management and Outcomes of Patients with Acute Coronary Syndromes. J Am Coll Cardiol. 2001;38:2114-2130.
15. Mosca L, Appel LJ, Benjamin EJ, et al. Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women. Circulation. 2004; 109:672-693.
16. American Diabetes Association. Standards of Medical Care in Diabetes- 2008. Diabetes Care. 2008;31:S12-S54.
17. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: A systemic review. JAMA. 2007;298: 786-798.
18. Robbins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events. JAMA. 2001;285: 1585-1591.
19. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. New England Journal of Medicine Website. Available at: Https://nejm.org. Accessed March 25, 2010.
20. Lopez-Sendon J, Mosca L, et al. Effects of torcetrapid in patient at high risk of coronary events. N Engl J Med. 2007;357: 2109-2222.
21. Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes. AIM-HIGH Cholesterol Management Web site. Available at: Http:// www.aimhigh-heart.com/process.shtml. Updated unknown. Accessed August 20, 2009.
22. HPS2-THRIVE: Treatment of High density lipoprotein to Reduce the Incidence of Vascular Events. HPS2-THRIVE. Clinical Trials Web site. Available at: Http://clinicaltrials.gov/ct2/show/NCT00461630. Accessed March 22, 2010.